Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Antibodies for biodefense.

Froude JW, Stiles B, Pelat T, Thullier P.

MAbs. 2011 Nov-Dec;3(6):517-27. doi: 10.4161/mabs.3.6.17621. Epub 2011 Nov 1. Review.

2.

Pathogen-specific recombinant human polyclonal antibodies: biodefence applications.

Bregenholt S, Haurum J.

Expert Opin Biol Ther. 2004 Mar;4(3):387-96. Review.

PMID:
15006732
3.

Persistence of category A select agents in the environment.

Sinclair R, Boone SA, Greenberg D, Keim P, Gerba CP.

Appl Environ Microbiol. 2008 Feb;74(3):555-63. Epub 2007 Dec 7. Review. No abstract available.

4.

[Practical strategies against bioterrorism].

Matsumoto T.

Nihon Rinsho. 2007 Dec;65(12):2363-73. Review. Japanese.

PMID:
18069284
5.

Bacillus anthracis, Francisella tularensis and Yersinia pestis. The most important bacterial warfare agents - review.

Pohanka M, Skl√°dal P.

Folia Microbiol (Praha). 2009;54(4):263-72. doi: 10.1007/s12223-009-0046-1. Epub 2009 Oct 14. Review.

PMID:
19826916
6.

Recognition and management of bioterrorism infections.

O'Brien KK, Higdon ML, Halverson JJ.

Am Fam Physician. 2003 May 1;67(9):1927-34. Review.

7.

Cutaneous manifestations of category A bioweapons.

Aquino LL, Wu JJ.

J Am Acad Dermatol. 2011 Dec;65(6):1213.e1-1213.e15. doi: 10.1016/j.jaad.2010.08.040. Epub 2011 Jul 20. Review.

PMID:
21777993
8.

Histopathology and immunohistochemistry in the diagnosis of bioterrorism agents.

Guarner J, Zaki SR.

J Histochem Cytochem. 2006 Jan;54(1):3-11. Epub 2005 Sep 7. Review.

PMID:
16148309
9.

Being prepared: bioterrorism and mass prophylaxis: part I.

Weant KA, Bailey AM, Fleishaker EL, Justice SB.

Adv Emerg Nurs J. 2014 Jul-Sep;36(3):226-38; quiz 239-40. doi: 10.1097/TME.0000000000000029.

PMID:
25076398
10.

Diagnosis and management of suspected cases of bioterrorism: a pediatric perspective.

Patt HA, Feigin RD.

Pediatrics. 2002 Apr;109(4):685-92. Review.

PMID:
11927716
11.

Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections.

Bregenholt S, Jensen A, Lantto J, Hyldig S, Haurum JS.

Curr Pharm Des. 2006;12(16):2007-15. Review.

PMID:
16787244
12.

Vaccines, biological warfare, and bioterrorism.

Polgreen PM, Helms C.

Prim Care. 2001 Dec;28(4):807-21, vii.

PMID:
11739031
13.

Threats in bioterrorism. I: CDC category A agents.

Darling RG, Catlett CL, Huebner KD, Jarrett DG.

Emerg Med Clin North Am. 2002 May;20(2):273-309. Review.

PMID:
12120480
14.

DNA vaccines for biodefense.

Dupuy LC, Schmaljohn CS.

Expert Rev Vaccines. 2009 Dec;8(12):1739-54. doi: 10.1586/erv.09.132. Review.

PMID:
19943766
15.

[Bioterrorism].

Sata T.

Nihon Hoigaku Zasshi. 2005 Oct;59(2):119-25. Review. Japanese.

PMID:
16296383
16.

Vaccines against biologic agents: uses and developments.

Ales NC, Katial RK.

Respir Care Clin N Am. 2004 Mar;10(1):123-46. Review.

PMID:
15062232
17.

[Recombinant antibodies against bioweapons].

Thullier P, Pelat T, Vidal D.

Med Sci (Paris). 2009 Dec;25(12):1145-8. doi: 10.1051/medsci/200925121145. Review. French.

18.

Being prepared: bioterrorism and mass prophylaxis: part II.

Weant KA, Bailey AM, Fleishaker EL, Justice SB.

Adv Emerg Nurs J. 2014 Oct-Dec;36(4):307-17; quiz 318-9. doi: 10.1097/TME.0000000000000034. Review.

PMID:
25356890
19.

Therapeutic options for diseases due to potential viral agents of bioterrorism.

Bronze MS, Greenfield RA.

Curr Opin Investig Drugs. 2003 Feb;4(2):172-8. Review.

PMID:
12669378
20.

Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.

Zhu Z, Dimitrov AS, Chakraborti S, Dimitrova D, Xiao X, Broder CC, Dimitrov DS.

Expert Rev Anti Infect Ther. 2006 Feb;4(1):57-66. Review.

PMID:
16441209
Items per page

Supplemental Content

Write to the Help Desk